Ben Nangombe, executive director in the health ministry, told Reuters on Thursday that 52,261 AstraZeneca vaccines will expire on Tuesday next week, while 215,996 Pfizer shots will be destroyed in January and February if they find no takers as vaccine hesitancy rises.
Namibia, which has started vaccinating 12- to 17-year olds with the Pfizer vaccine after the WHO said on Nov. 15 that it is suitable for people in that age group, has 809,414 doses available nationally.
The southern African nation recorded 15 new cases on Tuesday to bring the number of active cases to 85 compared to a peak of 2,547 cases in a single day on June 24.
Only 298,503, or 20% of an estimated eligible population of 1.5 million, have been fully vaccinated in Namibia, with the Chinese-made Sinopharm vaccine the most used after 145,483 people received two doses since the country’s vaccination programme started in March.
The Russian-made Sputnik V vaccine has been used the least, with only 71 people fully vaccinated before its rollout was suspended on Oct. 23, days after the drugs regulator in neighbouring South Africa flagged concerns about its safety for people at risk of HIV.
South African health regulator SAHPRA decided against approving an emergency use application for Sputnik V after some studies suggested vaccines using the Adenovirus Type 5 vector – which Sputnik V does – can lead to higher susceptibility to HIV in men.
South Africa and Namibia have high HIV prevalence rates.
By Nyasha Nyaungwa.
(Reporting by Nyasha Nyaungwa; editing by Wendell Roelf and Giles Elgood)
Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]